The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London is one of Europe’s top centres for mental health and related neurosciences research. World-leading research from the IoPPN has made and continues to impact how we understand, prevent and treat mental illness and other conditions that affect the brain.
At the Centre for Affective Disorders, The Psychedelic Trials Group is undertaking controlled clinical trials with psychedelics & related compounds. Dr James Rucker and Professor Allan Young lead these trials. The research team at KCL are working closely with several companies in the space, including COMPASS Pathways, MAPS and Beckley Psytech, investigating substances like MDMA, psilocybin and 5-MeO-DMT.
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates